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Abstract
Background: Haemorrhage is a common cause of death in trauma patients. Although transfusions are extensively used in
the care of bleeding trauma patients, there is uncertainty about the balance of risks and benefits and how this balance
depends on the baseline risk of death. Our objective was to evaluate the association of red blood cell (RBC) transfusion with
mortality according to the predicted risk of death.
Methods and Findings: A secondary analysis of the CRASH-2 trial (which originally evaluated the effect of tranexamic acid
on mortality in trauma patients) was conducted. The trial included 20,127 trauma patients with significant bleeding from
274 hospitals in 40 countries. We evaluated the association of RBC transfusion with mortality in four strata of predicted risk
of death:,6%, 6%–20%, 21%–50%, and.50%. For this analysis the exposure considered was RBC transfusion, and the main
outcome was death from all causes at 28 days. A total of 10,227 patients (50.8%) received at least one transfusion. We found
strong evidence that the association of transfusion with all-cause mortality varied according to the predicted risk of death
(p-value for interaction ,0.0001). Transfusion was associated with an increase in all-cause mortality among patients with ,
6% and 6%–20% predicted risk of death (odds ratio [OR] 5.40, 95% CI 4.08–7.13, p,0.0001, and OR 2.31, 95% CI 1.96–2.73,
p,0.0001, respectively), but with a decrease in all-cause mortality in patients with .50% predicted risk of death (OR 0.59,
95% CI 0.47–0.74, p,0.0001). Transfusion was associated with an increase in fatal and non-fatal vascular events (OR 2.58,
95% CI 2.05–3.24, p,0.0001). The risk associated with RBC transfusion was significantly increased for all the predicted risk of
death categories, but the relative increase was higher for those with the lowest (,6%) predicted risk of death (p-value for
interaction ,0.0001). As this was an observational study, the results could have been affected by different types of
confounding. In addition, we could not consider haemoglobin in our analysis. In sensitivity analyses, excluding patients who
died early; conducting propensity score analysis adjusting by use of platelets, fresh frozen plasma, and cryoprecipitate; and
adjusting for country produced results that were similar.
Conclusions: The association of transfusion with all-cause mortality appears to vary according to the predicted risk of death.
Transfusion may reduce mortality in patients at high risk of death but increase mortality in those at low risk. The effect of
transfusion in low-risk patients should be further tested in a randomised trial.
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Introduction
Haemorrhage is a leading cause of death in trauma patients,
responsible for approximately 30% to 40% of trauma-related
deaths [1,2]. Although red blood cell (RBC) transfusion is often
used in the management of bleeding trauma patients, there is
considerable uncertainty regarding the balance of risks and
benefits [3,4].
RBC transfusion is a scarce and expensive intervention with
potential adverse effects, including allergic reaction, transfusion-
related lung injury, graft versus host disease, and infection.
Furthermore, supplies of blood are lower, and the risks from
transfusion higher, in low- and middle-income countries, where
most bleeding deaths occur [5].
A systematic review showed that RBC transfusion is associated
with increased morbidity and mortality in critically ill patients,
including trauma patients [6]. Nevertheless, the included studies
were observational, and it is likely that some of the effect observed
was due to confounding by indication, with transfusion being
offered to more severely ill patients. A more recent systematic
review of randomised trials evaluated the effect of different
haemoglobin or haematocrit thresholds for blood transfusion in
haemodynamically stable critically ill patients. It found that a more
restrictive approach (transfusion only when haemoglobin levels
were below 70 or 80 g/l) reduced in-hospital mortality without
any increase in adverse events [7].
However, most RBC transfusion in trauma patients occurs early
after hospital admission, when haematocrit level is not a reliable
indicator of the extent of bleeding, and clinicians must use physical
signs, diagnostic tests, and clinical judgment to decide whether or
not a RBC transfusion is indicated [8].
It is possible that the effect of RBC transfusion on mortality
depends on the underlying risk. We hypothesized that there may
be a beneficial effect among patients at high risk of death but a
harmful effect in those patients at low risk of death. Even if the
relative effect is similar, the absolute effect and cost-effectiveness
could vary according to underlying risk, and so a stratified
approach to RBC transfusion might be justified. To the best of our
knowledge, this hypothesis has not been tested before in trauma
patients. Using a large international cohort of trauma patients with
bleeding, we evaluated the association of RBC transfusion with
mortality according to the predicted risk of death.
Methods
Ethics Statement
This study received ethics approval from the London School of
Hygiene & Tropical Medicine.
Aims
The primary objective of the study was to evaluate the
association of RBC transfusion with all-cause mortality at 28 days
(or hospital discharge) according to predicted risk of death at
hospital admission. The secondary objective was to evaluate the
association of RBC transfusion with fatal and non-fatal vascular
occlusive events.
Sample
The study cohort included all patients from the CRASH-2
clinical trial. The trial included 20,127 trauma patients with, or at
risk of, significant bleeding within 8 h of injury, and evaluated the
effect of tranexamic acid on all-cause mortality. The trial was
undertaken in 274 hospitals in 40 countries. Detailed information
on the methods and results of the CRASH-2 trial have been
published previously [9].
Outcomes
The primary outcome of this analysis was death from all causes
stratified by baseline risk. We also reported specific causes of death
(bleeding, head injury, multi-organ failure, myocardial infarction,
stroke, pulmonary embolism, and other causes), and we conducted
a secondary analysis exploring the association of RBC transfusion
with fatal and non-fatal vascular occlusive events including
myocardial infarction, stroke, deep vein thrombosis, and pulmo-
nary embolism. All events were measured at 28 days or hospital
discharge. Cause of death was defined by the investigators using
their clinical judgment.
Interventions and Comparisons
We compared the association of RBC transfusion with the
outcomes versus that of no RBC transfusion. For this analysis we
compared two groups: those who received at least one RBC
transfusion (transfused) versus those patients who did not receive
any RBC transfusion (non-transfused).
Statistical Analysis
The characteristics of patients were tabulated and compared
according to whether the patient underwent a transfusion.
Univariable comparisons were made using a logistic regression
model by treating each variable as a categorical or continuous co-
variate as appropriate.
For each patient we estimated the predicted risk of death from
all causes using a validated model, and categorised patients into
four pre-specified strata (,6%, 6%–20%, 21%–50%, and .50%).
The prognostic model we used was developed using 20,127
trauma patients with, or at risk of, significant bleeding within 8 h
of injury. The model development was conducted with a backward
stepwise approach, and the predictors included in the final model
were Glasgow Coma Scale, age, heart rate, systolic blood pressure,
time since injury, type of injury, and geographical region. Full
details of model development and validation have been published
elsewhere [10] (see Text S1). Although risk is a continuous
variable, we decided to use risk categories for simplifying its use in
clinical practice. The risk categories used were identical to the ones
reported in the original prognostic model, and the cutoffs were
decided with the feedback from prognostic model users and by
looking at previous publications [10].
The number of patients and number of deaths were tabulated
by transfusion status. Odds ratios (ORs) and risk differences,
together with 95% confidence intervals, comparing RBC transfu-
sion to no RBC transfusion were calculated within each of the pre-
specified risk categories as defined previously [10]. Interaction tests
were conducted using logistic regression to formally assess whether
the impact of RBC transfusion differed according to underlying
risk, with risk considered as a continuous variable.
Because RBC transfusion practices vary and could be associated
with different risks according to the region of the world, we also
examined the association with death from all causes separately for
four geographical regions.
To identify a potential non-linear interaction between
transfusion and baseline risk, patients were also categorised
into ten risk groups containing approximately one-tenth of the
primary outcome each, and the association of RBC transfusion
with death from all causes was evaluated within each of these
categories.
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Table 1. Baseline characteristics by transfusion status.
Characteristic Subcategory
Number with Missing
Values All Patients Transfusion
Yes No p-Value
Total 270 20,127 10,227 (50.8%) 9,900 —
Country income High 0 414 343 (82.9%) 71 —
Middle 0 19,408 9,715 (50.1%) 9,693 ,0.0001
Low 0 305 169 (55.4%) 136 ,0.0001
Tranexamic acid Placebo 0 10,067 5,160 (51.3%) 4,907 —
Active 0 10,060 5,067 (50.4%) 4,993 0.21
Time from injury to arrival at
hospital
#3 h 8 13,485 6,506 (48.2%) 6,979 —
.3 h 6,634 3,715 (56.0%) 2,919 ,0.0001
Age (years) 1 30 (24 to 43) 31 (21 to 43) 30 (24 to 43) 0.9
Systolic blood pressure (mm Hg) 28 91 (80 to 110) 90 (80 to 100) 100 (90 to 120) ,0.0001
Respiratory rate (per min) 186 22 (20 to 26) 22 (20 to 28) 22 (19 to 26) ,0.0001
Heart rate (per min) 137 105 (90 to 120) 110 (96 to 120) 100 (88 to 112) ,0.0001
Glasgow Coma Scale 23 15 (11 to 15) 14 (10 to 15) 15 (12 to 15) ,0.0001
Penetrating injury No 0 13,605 6,998 (51.4%) 6,607 —
Yes 0 6,522 3,229 (49.5%) 3,293 0.01
Mortality at 28 days No 0 17,051 8,206 (48.1%) 8,845 ,0.0001
Yes 0 3,076 2,021 (65.7%) 1,055
Predicted risk of deatha ,6% 8,706 3,406 (39.1%) 5,300 —
6% to 20% 6,850 3,905 (57.0%) 2,945 ,0.0001
.20% to 50% 2,758 1,761 (63.9%) 997 ,0.0001
.50% 1,543 960 (62.2%) 583 ,0.0001
Data are presented as number, number (percent), or median (interquartile range).
aFrom a logistic regression model fitting each covariate as a categorical or continuous variable. Predicted risk of death was not calculated for those with missing values.
doi:10.1371/journal.pmed.1001664.t001
Table 2. Clinical outcomes by red blood cell transfusion.
Outcome Transfusion (n=10,227) No Transfusion (n=9,900) Total (n=20,127) p-Value
All-cause mortality 2,021 (19.8%) 1,055 (10.7%) 3,076 (15.3%) ,0.0001
Cause-specific mortality
Bleeding 803 (7.9%) 260 (2.6%) 1,063 (5.3%) ,0.0001
Head injury 624 (6.1%) 600 (6.1%) 1,224 (6.1%) 0.9
Multi-organ failure 343 (3.4%) 99 (1.0%) 442 (2.2%) ,0.0001
Myocardial infarction 22 (0.2%) 7 (0.1%) 29 (0.1%) 0.01
Stroke 7 (0.1%) 6 (0.1%) 13 (0.1%) 0.83
Pulmonary embolism 25 (0.2%) 14 (0.1%) 39 (0.2%) 0.1
Other causes 197 (1.9%) 69 (0.7%) 266 (1.3%) ,0.0001
Other outcomes (fatal and non-fatal)
Myocardial infarction 67 (0.7%) 23 (0.2%) 90 (0.4%) ,0.0001
Stroke 79 (0.8%) 44 (0.4%) 123 (0.6%) 0.003
Pulmonary embolism 109 (1.1%) 34 (0.3%) 143 (0.7%) ,0.0001
Non-fatal deep vein thrombosis 69 (0.7%) 12 (0.1%) 81 (0.4%) ,0.0001
Vascular occlusive eventsa 267 (2.6%) 102 (1.0%) 369 (1.8%) ,0.0001
Data are presented as number (percent) of patients.
aMyocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis.
doi:10.1371/journal.pmed.1001664.t002
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We conducted complete case analyses, as the amount of missing
data was very low (1%).
Sensitivity analyses. To take into account a potential
survival bias we also reported the association of RBC transfusion
with all-cause mortality excluding patients who died on day ‘‘0’’
(first day of hospital arrival).
To examine the impact of possible confounding by indication,
we calculated propensity scores for all patients using logistic
regression, with blood transfusion as the outcome. Factors
included in the model were those likely to influence the decision
to transfuse, including age, gender, income region (high, middle,
or low), systolic blood pressure, heart rate, respiratory rate,
Glasgow Coma Scale, type of injury (penetrating or blunt), time
since injury, and tranexamic acid use. The distribution of
propensity scores amongst all transfused and non-transfused
patients was then compared, and we excluded all patients with
scores in the upper and lower 5% of the score distribution. Any
patients whose propensity scores were outside the overlapping area
of the distributions of transfused and non-transfused patients were
also excluded, to avoid making comparisons between patients with
too many underlying differences. With this reduced study
population, we then evaluated the association of transfusion with
all-cause mortality according to the predicted risk of death in each
of the pre-specified mortality strata, adjusting by the propensity
score (as a continuous variable).
Finally, to take into account potential confounding by
geographical variation in the types of blood products used for
transfusion, we adjusted the comparison within each predicted risk
group by use of platelets, fresh frozen plasma, and cryoprecipitate
and by country using logistic regression.
Stata Statistical Software Release 11 (StataCorp) was used for
the analysis.
Results
The baseline characteristics of CRASH-2 trial patients accord-
ing to their RBC transfusion status are displayed in Table 1. A
total of 10,227 patients (50.8%) received RBC transfusion. Patients
from high-income countries, and those who arrived at hospital
more than 3 h after the injury, had lower systolic blood pressure or
Glascow Coma Score, had higher heart rate or respiratory rate, or
had blunt injury were more likely to receive RBC transfusion (p,
0.0001 for all comparisons, except p = 0.010 for blunt versus
penetrating injuries). Patients in the lowest predicted risk of death
category (,6%) were less likely to receive RBC transfusions.
All-cause mortality was higher in patients who received RBC
transfusion (Table 2). A total of 2,021 (19.8%) patients who
received a RBC transfusion died, while 1,055 (10.7%) patients who
did not receive RBC transfusion died (OR 2.06, 95% CI 1.91–
2.24, p,0.0001). Deaths from bleeding (OR 3.16, 95% CI 2.74–
3.64, p,0.0001), multi-organ failure (OR 3.44, 95% CI 2.74–4.30,
p,0.0001), myocardial infarction (OR 3.05, 95% CI 1.30–7.13,
p = 0.010), and other causes (OR 2.80, 95% CI 2.12–3.69, p,
0.0001) were more frequent in patients who received a RBC
transfusion than in those who did not receive one.
A total of 267 (2.6%) patients who received RBC transfusion
had a fatal or non-fatal vascular occlusive event, in comparison to
102 (1.0%) of those patients who did not receive a RBC
transfusion (OR 2.58, 95% CI 2.05–3.24, p,0.0001).
As shown in Table 3 we found strong evidence that the
association of RBC transfusion with all-cause mortality differed
according to the predicted risk of death (p-value for interaction ,
0.0001). A total of 270 patients were excluded from this analysis
because at least one variable of the prognostic model was missing
(Table S1 provides details of patient characteristics for individuals
Table 3. Mortality by category of predicted risk of death and red blood cell transfusion.
Predicted Risk
of Deatha Deaths according to Transfusion Status of Patient OR (95% CI)
Risk Difference
(95% CI) p-Value
Transfusion No Transfusion
,6% 217/3,406 (6.4%) 66/5,300 (1.2%) 5.40 (4.08 to 7.13) 5.1% (4.3% to 6.0%) ,0.0001
6%–20% 591/3,905 (15.1%) 211/2,945 (7.2%) 2.31 (1.96 to 2.73) 8.0% (6.5% to 9.4%) ,0.0001
21%–50% 557/1761 (31.6%) 334/997 (33.5%) 0.92 (0.78 to 1.08) 21.9% (25.5% to 1.8%) 0.31
.50% 566/960 (59.0%) 413/583 (70.8%) 0.59 (0.47 to 0.74) 211.9% (216.7% to 27.1%) ,0.0001
Interaction between RBC transfusion and predicted risk of death on the OR, p,0.0001 (chi-square = 227 with one degree of freedom).
aRisk group determined according to model published in [10].
doi:10.1371/journal.pmed.1001664.t003
Table 4. Mortality by category of predicted risk of death and red blood cell transfusion excluding deaths on day 0.
Predicted Risk of
Deatha Deaths according to Transfusion Status of Patient OR (95% CI) Risk Difference (95% CI) p-Value
Transfusion No Transfusion
,6% 169/3,358 (5.0%) 47/5,281 (0.9%) 5.90 (4.26 to 8.18) 4.1% (3.4% to 4.9%) ,0.0001
6%–20% 431/3,745 (11.5%) 122/2,856 (4.3%) 2.91 (2.37 to 3.59) 7.2% (6.0% to 8.5%) ,0.0001
21%–50% 406/1,610 (25.2%) 198/861 (23.0%) 1.13 (0.93 to 1.37) 2.2% (21.3% to 5.7%) 0.22
.50% 370/764 (48.4%) 200/370 (54.1%) 0.80 (0.62 to 1.02) 25.6% (211.8% to 0.6%) 0.076
Interaction between RBC transfusion and predicted risk of death on the OR, p,0.0001 (chi-square = 150 with one degree of freedom).
aRisk group determined according to model published in [10].
doi:10.1371/journal.pmed.1001664.t004
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with missing data). The risk of all-cause mortality associated with
RBC transfusion was increased in patients with ,6% predicted
risk of death, (217 [6.4%] in transfused group versus 66 [1.2%] in
non-transfused group; OR 5.40, 95% CI 4.08–7.13, p,0.0001).
RBC transfusion was also associated with an increase in all-cause
mortality in patients with 6%–20% predicted risk of death (591
[15.1%] in transfused group versus 211 [7.2%] in non-transfused
group; OR 2.31, 95% CI 1.96–2.73, p,0.0001). Among patients
with a predicted risk of death of 21%–50%, all-cause mortality was
similar in the two groups (557 [31.6%] in transfused group versus
334 [33.5%] in non-transfused group; OR 0.92, 95% CI 0.78–
1.08, p = 0.31), while the risk of all-cause mortality was signifi-
cantly decreased with RBC transfusion in patients with .50%
predicted risk of death (566 [59%] in transfused group versus 413
[70.8%] in non-transfused group; OR 0.59, 95% CI 0.47–0.74,
p,0.0001).
In absolute terms, there were 5.1 (95% CI 4.3 to 6.0) more
deaths per 100 patients associated with RBC transfusion in the
group with the lowest predicted risk of death but 11.9 (95% CI 7.1
to 16.7) fewer deaths per 100 patients associated with RBC
transfusion in the group with the highest predicted risk.
The sensitivity analysis (excluding 1,086 patients who died at
day 0) showed similar results, indicating that the association of
RBC transfusion with all-cause mortality differed according to the
predicted risk of death (p-value for interaction ,0.0001) (Table 4).
Propensity score analysis (excluding 2,011 patients with extreme
propensity score values) showed similar results, with strong
evidence of interaction of the association of RBC transfusion with
all-cause mortality according to the predicted risk of death (p-value
for interaction ,0.0001) (Table 5). The sensitivity analysis
adjusting for use of platelets, fresh plasma, and cryoprecipitate
and for country also showed a similar pattern and strong evidence
of interaction (Table 6).
To explore the association of RBC transfusion with all-cause
mortality further, we created ten groups of predicted risk of death
containing approximately one-tenth of the primary outcome each.
As can be seen in Figure 1, RBC transfusion showed a trend from
a positive association (harmful) to a negative association (benefi-
cial) with all-cause mortality according to predicted risk of death.
RBC transfusion was associated with an increase in all-cause
mortality at low predicted risk of death and a decrease in all-cause
mortality at high predicted risk of death. The change in direction
of the association of transfusion (from harmful to beneficial) with
all-cause mortality occurred around a predicted risk of death of
about 25%.
We found strong evidence that the association of RBC
transfusion with all-cause mortality differed according to the
predicted risk of death (p-value for interaction ,0.0001) for each
of geographical regions considered (Table 7). Although effect
estimates and confidence intervals varied by geographical region,
we found the same pattern of association of RBC transfusion and
all-cause mortality (positive at low predicted risk of death and
negative at high predicted risk of death).
We also found strong evidence that the association of RBC
transfusion with vascular occlusive events differed according to the
predicted risk of death (p-value for interaction ,0.0001) (Table 8).
The risk associated with RBC transfusion was significantly
increased for all the predicted risk of death categories, but the
relative increase was higher for those with the lowest predicted risk
of death. The OR of vascular occlusive events associated with
RBC transfusion was 4.92 (95% CI 2.80–8.65, p,0.0001)
in patients with ,6% predicted risk of death, 1.66 (95% CI
Table 5. Mortality by category of predicted risk of death and red blood cell transfusion adjusted for propensity score.
Predicted Risk of
Deatha Deaths according to Transfusion Status of Patient OR (95% CI) Risk Difference (95% CI) p-Value
Transfusion No Transfusion
,6% 203/3,128 (6.5%) 61/4,633 (1.3%) 4.87 (3.62 to 6.55) 5.0% (4.0% to 5.9%) ,0.0001
6%–20% 558/3,758 (14.8%) 205/2,874 (7.1%) 2.22 (1.86 to 2.63) 7.5% (6.0% to 9.0%) ,0.0001
21%–50% 462/1,450 (31.9%) 288/909 (31.7%) 1.08 (0.90 to 1.30) 1.8% (22.2% to 5.7%) 0.42
.50% 394/644 (61.2%) 314/449 (69.9%) 0.69 (0.53 to 0.90) 28.3% (214.1% to 22.5%) 0.006
Interaction between RBC transfusion and predicted risk of death on the OR, p,0.0001 (chi-square = 151).
aRisk group determined according to model published in [10].
doi:10.1371/journal.pmed.1001664.t005
Table 6. Mortality by category of predicted risk of death and red blood cell transfusion (adjusted analysis).
Predicted Risk of Deatha Deaths according to Transfusion Status of Patient ORb (95% CI) p-Value
Transfusion No Transfusion
,6% 217/3,346 (6.5%) 66/5,191 (1.3%) 3.68 (2.71 to 5.01) ,0.0001
6%–20% 591/3,750 (15.8%) 211/2,853 (7.4%) 1.92 (1.59 to 2.30) ,0.0001
21%–50% 555/1,761 (31.7%) 332/993 (33.4%) 0.95 (0.78 to 1.16) 0.62
.50% 559/947 (59.0%) 403/573 (70.3%) 0.82 (0.62 to 1.07) ,0.0001
Interaction between RBC transfusion and predicted risk of death on the OR, p,0.0001 (chi-square = 188 with one degree of freedom).
aRisk group determined according to model published in [10].
bOR adjusted for country as well as use of platelets (n= 806), fresh frozen plasma (n= 2,633), and cryoprecipitate (n= 392). In total, 2,726 (13.5%) patients received one of
these blood products.
doi:10.1371/journal.pmed.1001664.t006
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1.13–2.46, p = 0.009) in patients with 6%–20% predicted risk of
death, 1.80 (95% CI 1.16–2.80, p = 0.006) in patients with 21%–
50% predicted risk of death, and 1.58 (95% CI 0.93–2.68,
p = 0.081) in patients with .50% predicted risk of death
Discussion
Main Findings
The association of blood transfusion with all-cause mortality
appears to vary according to the predicted risk of death. We found
that in patients with a predicted risk of #20%, transfusion was
associated with an increase in all-cause mortality, while in those
patients with high predicted risk of death (.50%), transfusion was
associated with reduced mortality. This pattern from harmful to
beneficial association was also found when the association of
transfusion with mortality was analysed in ten risk categories, and
when we analysed patients from different geographical regions
separately. In spite of these findings, because of potential biases
inherent in this observational study, our findings should be
considered cautiously.
Because an increase in vascular occlusive events was hypoth-
esized as one of the possible mechanisms by which RBC
transfusion might be harmful, we conducted a stratified analysis
for these outcomes [11,12]. Although we found that the
association of transfusion with fatal and non-fatal vascular
occlusive events varies according to the predicted risk of death,
Figure 1. Odds ratio of death for transfusion compared to no transfusion by risk category.
doi:10.1371/journal.pmed.1001664.g001
Table 7. Mortality with red blood cell transfusion by risk category and geographical region.
Predicted Risk of Death OR (95% CI)
a by Geographical Region
Asia
Central and South
America Africa
Europe, North America, and
Australasia
,6% 4.94 (2.86 to 8.54) 6.55 (4.16 to 10.32) 2.92 (1.67 to 5.10) 13.01 (4.42 to 38.37)
6%–20% 2.31 (1.74 to 3.07) 2.01 (1.47 to 2.75) 1.77 (1.30 to 2.40) 5.55 (3.15 to 9.79)
21%–50% 1.06 (0.83 to 1.35) 0.80 (0.55 to 1.15) 0.49 (0.33 to 0.71) 1.48 (0.90 to 2.44)
.50% 0.87 (0.62 to 1.22) 0.67 (0.40 to 1.12) 0.44 (0.26 to 0.73) 0.45 (0.27 to 0.76)
Deaths/total 1,158/7,250 (16.0%) 737/5,173 (14.2%) 707/4,761 (14.8%) 353/2,673 (13.2%)
Interaction between RBC transfusion and predicted risk of death on the OR, p,0.0001 for each continent grouping.
aOR for RBC transfusion versus no RBC transfusion. Risk group determined according to model published in [10].
doi:10.1371/journal.pmed.1001664.t007
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transfusion was positively associated with vascular occlusive events
(harmful) across all risk strata regardless of the predicted risk of
death category.
Strengths and Limitations
Our study has a number of strengths. The CRASH-2 trial was a
prospective cohort of bleeding trauma patients, with standardised
collection of data on prognostic factors, a large sample size, few
missing data, and low loss to follow-up [9]. It included hospitals
from low-, middle-, and high-income countries. The prognostic
model used in this analysis has shown good performance when
externally validated [10]. The study hypothesis was pre-specified,
including the risk strata and the direction of the association of
transfusion according to the predicted risk of death. The study
protocol was registered.
On the other hand, our study has serious limitations. Although
our data were from a randomised clinical trial, blood transfusion
was not a randomised intervention, and therefore our inferences
are vulnerable to confounding [13]. Potential confounding could
be suspected because baseline characteristics for transfused and
non-transfused patients were different, and those receiving
transfusion were at a higher risk of death due to bleeding.
Furthermore, there is the possibility of biases acting in different
directions depending on the predicted risk of death. For example,
in the high-risk group (.50% risk of death), the negative
association (beneficial) of RBC transfusion with all-cause mortality
could be due to survival bias, since only those who survive are
eligible to receive a transfusion [14]. Unfortunately, it was not
possible to conduct a time-updated model whereby the period
before transfusion was taken into account, since the time of the
transfusion was not recorded. Nonetheless, when we attempted to
avoid this bias by limiting the analysis to those patients who
survived beyond day 0 and therefore had the same opportunity to
be transfused, the interaction remained strong.
Conversely, among the low-risk patients, those receiving RBC
transfusion might have been at higher risk of death (‘‘confounding
by indication’’). Propensity scores are useful in observational
studies, as they help the researcher to determine whether groups of
users and non-users are comparable, and have the potential to
reduce confounding by indication [15]. When we conducted an
analysis using propensity scores, the results were similar. One
potential limitation of using this analytical approach in our study is
that there might be a time gap between the variables used in the
propensity score (recorded at hospital admission) and the
transfusion indication, and this time gap could result in patients
being classified as lower risk than they are at the actual time of
transfusion. However, the variables included in the propensity
scores have been shown to be good predictors of 28-d mortality
(which is the transfusion window included in this analysis), so the
potential of ‘‘misclassifying’’ to a lower risk category a large
proportion of patients using this approach is low [10].
Another limitation of our study is that we could not consider
haemoglobin in our analysis. However, our analysis is still
informative for current clinical practice, as the indications for a
large proportion of RBC transfusions in trauma patients early after
hospital admission are based on clinical signs (such as the ones
included in our prognostic model) rather than on haemoglobin
levels. Furthermore, as mentioned above, the clinical signs
included in our prognostic model, such as heart rate and blood
pressure, have been shown to be highly predictive of adverse
outcomes in patients with trauma and bleeding, and specifically
the prognostic model used in our analysis has shown good
predictive performance [10].
Finally, the association of blood transfusion with all-cause
mortality could have been influenced by the type of blood product
received (i.e., whole blood or RBCs) in different countries.
Although we did not have this information available, the same
pattern and strong evidence for interaction according to baseline
risk was found in all the geographical regions. Furthermore, when
we further adjusted by use of platelets, fresh frozen plasma, and
cryoprecipitate and by country, results were similar.
Comparison with Previous Studies
Previous studies have shown that RBC transfusions are
associated with an increased risk of complications in trauma
patients. A systematic review evaluating the association of
RBC transfusion with mortality in critically ill patients
identified 45 observational studies, and in 42 of them the risks
of RBC transfusion outweighed the benefits [6]. The studies
included were observational and therefore prone to different
types of bias, and, importantly, they did not analyse the
association of RBC transfusion with mortality according to
baseline risk.
The findings from another systematic review that evaluated the
effect of liberal versus restricted transfusion thresholds (haemoglo-
bin or haematocrit triggers) in critically ill patients support the use
of restrictive transfusion triggers (haemoglobin levels between 70
and 80 g/l) [7]. Nonetheless, haematocrit level is not a reliable
indicator of the extent of bleeding in the early hours after hospital
admission, when a substantial proportion of RBC transfusions
occur, and clinicians instead use clinical signs and their clinical
judgment to decide whether or not to mandate a RBC transfusion.
To the best of our knowledge, this is the first study to evaluate the
association of RBC transfusion with all-cause mortality stratified
by predicted risk of death, using simple clinical variables routinely
available at hospital admission.
Table 8. Vascular occlusive events (fatal and non-fatal) by category of predicted risk of death and red blood cell transfusion.
Predicted Risk of
Deatha
Vascular Occlusive Events according to Transfusion
Status of Patient OR (95% CI) Risk Difference (95% CI) p-Value
Transfusion No Transfusion
,6% 50/3,406 (1.5%) 16/5,300 (0.3%) 4.92 (2.80 to 8.65) 1.2% (0.7% to 1.6%) ,0.0001
6%–20% 81/3,905 (2.1%) 37/2,945 (1.3%) 1.66 (1.13 to 2.46) 0.8% (0.2% to 1.4%) 0.009
21%–50% 84/1,761 (4.8%) 27/997 (2.7%) 1.80 (1.16 to 2.80) 2.1% (0.6% to 3.5%) 0.006
.50% 51/960 (5.3%) 20/583 (3.4%) 1.58 (0.93 to 2.68) 1.9% (20.2% to 3.9%) 0.081
Interaction between RBC transfusion and predicted risk of death on the OR, p= 0.013.
aRisk group determined according to model published in [10].
doi:10.1371/journal.pmed.1001664.t008
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Implications for Practice and Research
Current recommendations for trauma and critically ill patients
state that transfusion is indicated for patients in ‘‘haemorrhagic
shock’’ or who are haemodynamically unstable, and that a
restrictive strategy (transfusion when haemoglobin ,70 g/l) is as
effective as a liberal strategy (transfusion when haemoglobin ,
100 g/l) for haemodynamically stable patients [16,17]. It is
important to highlight that only a small proportion of trauma
patients would present with haemorrhagic shock, and the vast
majority of trauma patients might be unstable but not at very high
risk of death [18,19]. Although RBC transfusion might be life-
saving for patients with haemorrhagic shock, uncertainty remains
about the best early transfusion strategy in other patients. Our
study suggests that blood transfusion could be harmful for those
patients whose predicted risk of death is low. However, as our
study was observational, important biases cannot be ruled out, and
we cannot claim a causal link. Therefore, this hypothesis should be
prospectively evaluated in a randomised controlled trial.
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Editors’ Summary
Background. Trauma—a serious injury to the body caused
by violence or an accident—is a major global health
problem. Every year, injuries caused by traffic collisions, falls,
blows, and other traumatic events kill more than 5 million
people (9% of annual global deaths). Indeed, for people
between the ages of 5 and 44 years, injuries are among the
top three causes of death in many countries. Trauma
sometimes kills people through physical damage to the
brain and other internal organs, but hemorrhage (serious
uncontrolled bleeding) is responsible for 30%–40% of
trauma-related deaths. Consequently, early trauma care
focuses on minimizing hemorrhage (for example, by using
compression to stop bleeding) and on restoring blood
circulation after blood loss (health-care professionals refer to
this as resuscitation). Red blood cell (RBC) transfusion is often
used for the management of patients with trauma who are
bleeding; other resuscitation products include isotonic saline
and solutions of human blood proteins.
Why Was This Study Done? Although RBC transfusion
can save the lives of patients with trauma who are bleeding,
there is considerable uncertainty regarding the balance of
risks and benefits associated with this procedure. RBC
transfusion, which is an expensive intervention, is associated
with several potential adverse effects, including allergic
reactions and infections. Moreover, blood supplies are
limited, and the risks from transfusion are high in low- and
middle-income countries, where most trauma-related deaths
occur. In this study, which is a secondary analysis of data
from a trial (CRASH-2) that evaluated the effect of tranexamic
acid (which stops excessive bleeding) in patients with
trauma, the researchers test the hypothesis that RBC
transfusion may have a beneficial effect among patients at
high risk of death following trauma but a harmful effect
among those at low risk of death.
What Did the Researchers Do and Find? The CRASH-2
trail included 20,127 patients with trauma and major
bleeding treated in 274 hospitals in 40 countries. In their
risk-stratified analysis, the researchers investigated the effect
of RBC transfusion on CRASH-2 participants with a predicted
risk of death (estimated using a validated model that
included clinical variables such as heart rate and blood
pressure) on admission to hospital of less than 6%, 6%–20%,
21%–50%, or more than 50%. That is, the researchers
compared death rates among patients in each stratum of
predicted risk of death who received a RBC transfusion with
death rates among patients who did not receive a
transfusion. Half the patients received at least one transfu-
sion. Transfusion was associated with an increase in all-cause
mortality at 28 days after trauma among patients with a
predicted risk of death of less than 6% or of 6%–20%, but
with a decrease in all-cause mortality among patients with a
predicted risk of death of more than 50%. In absolute figures,
compared to no transfusion, RBC transfusion was associated
with 5.1 more deaths per 100 patients in the patient group
with the lowest predicted risk of death but with 11.9 fewer
deaths per 100 patients in the group with the highest
predicted risk of death.
What Do These Findings Mean? These findings show
that RBC transfusion is associated with an increase in all-
cause deaths among patients with trauma and major
bleeding with a low predicted risk of death, but with a
reduction in all-cause deaths among patients with a high
predicted risk of death. In other words, these findings
suggest that the effect of RBC transfusion on all-cause
mortality may vary according to whether a patient with
trauma has a high or low predicted risk of death. However,
because the participants in the CRASH-2 trial were not
randomly assigned to receive a RBC transfusion, it is not
possible to conclude that receiving a RBC transfusion
actually increased the death rate among patients with a
low predicted risk of death. It might be that the patients with
this level of predicted risk of death who received a
transfusion shared other unknown characteristics (confound-
ers) that were actually responsible for their increased death
rate. Thus, to provide better guidance for clinicians caring for
patients with trauma and hemorrhage, the hypothesis that
RBC transfusion could be harmful among patients with
trauma with a low predicted risk of death should be
prospectively evaluated in a randomised controlled trial.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001664.
N This study is further discussed in a PLOS Medicine
Perspective by Druin Burch
N The World Health Organization provides information on
injuries and on violence and injury prevention (in several
languages)
N The US Centers for Disease Control and Prevention has
information on injury and violence prevention and control
N The National Trauma Institute, a US-based non-profit
organization, provides information about hemorrhage
after trauma and personal stories about surviving trauma
N The UK National Health Service Choices website provides
information about blood transfusion, including a personal
story about transfusion after a serious road accident
N The US National Heart, Lung, and Blood Institute also
provides detailed information about blood transfusions
N MedlinePlus provides links to further resources on injuries,
bleeding, and blood transfusion (in English and Spanish)
N More information in available about CRASH-2 (in several
languages)
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